Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: virus-like particles - Agilvax

Drug Profile

Research programme: virus-like particles - Agilvax

Alternative Names: AX 03; AX 14; Breast cancer immunotherapy - Agilvax; Dengue vaccine - Agilvax; Human papilloma virus vaccine - Agilvax; Malaria vaccine - Agilvax; Non-Hodgkin's lymphoma immunotherapy - Agilvax; Ovarian cancer immunotherapy - Agilvax; Pan-Ebola vaccine - Agilvax; Pan-Filovirus vaccine - Agilvax; Respiratory syncytial virus vaccine - Agilvax

Latest Information Update: 28 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agilvax
  • Class Virus-like particle vaccines
  • Mechanism of Action CD44 antigen modulators; Immunogenetic stimulants; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Dengue; Ebola virus infections; Human papillomavirus infections; Malaria; Non-Hodgkin's lymphoma; Ovarian cancer; Respiratory syncytial virus infections; Viral haemorrhagic fevers

Most Recent Events

  • 28 May 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA
  • 28 May 2021 No recent reports of development identified for research development in Ebola-virus-infections(Prevention) in USA (Parenteral)
  • 28 May 2021 No recent reports of development identified for research development in Viral-haemorrhagic-fevers(Prevention) in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top